Business Context and Reporting Period
This Form 8-K, dated August 28, 2025, reports a material transformation for Strata Critical Medical, Inc. (formerly Blade Air Mobility, Inc.). On August 28, 2025, the Company legally changed its name. On August 29, 2025, the Company completed the sale of its Passenger business to Joby Aero, Inc., effectively pivoting its operations to focus on critical medical services.
Key Financial Metrics and Transaction Details
- Transaction Consideration: The Company received approximately $76.0 million in consideration for the sale of its Passenger business, calculated based on a Joby Aviation closing price of $14.27 per share on August 28, 2025.
- Payment Structure: Consideration consisted of 5,325,585 shares of Joby Aviation common stock.
- Potential Additional Consideration: The Company may receive up to an additional $35.0 million in cash or Joby Aviation shares contingent on employee retention and financial performance targets over the next 18 and 12 months, respectively.
- Indemnity Holdbacks: Up to $10.0 million in consideration is held back as indemnity and may be released in the future.
- Financial Statements: Unaudited pro forma condensed consolidated financial information is provided in Exhibit 99.1; specific revenue, profit, cash flow, and debt figures for the current period are not detailed in the text of this filing.
Material Changes Versus Prior Period
- Asset Disposition: The Company divested its Passenger business, a core component of its prior operations.
- Corporate Identity: The Company changed its name from Blade Air Mobility, Inc. to Strata Critical Medical, Inc. and updated its Nasdaq ticker symbols to "SRTA" (Common Stock) and "SRTAW" (Warrants).
- Operational Restrictions: The Company entered into a Restrictive Covenant Agreement limiting its ability to offer short-distance or jet charter services for eight and three years, respectively.
- Commercial Partnership: A Commercial Agreement grants Joby Buyer the right (but not obligation) to provide medical transport services to the Company for eight years.
Guidance, Outlook, and Management Commentary
- Updated Guidance: The Company issued updated financial guidance for fiscal year 2025 in a press release (Exhibit 99.2), though specific numerical targets are not included in this filing text.
- Leadership Changes: Effective at closing, Melissa Tomkiel and William Heyburn assumed the roles of Co-Chief Executive Officers. Both were also appointed to the Board of Directors.
- Board Composition: The Board expanded from eight to ten directors. John Borthwick and Kenneth Lerer resigned effective at closing, with no disagreement cited.
- Corporate Governance: The Company amended its Bylaws to formalize the Co-CEO structure, require the election of a Lead Independent Director under specific conditions, and revise stockholder nomination procedures.
Investor Verification Checklist
- Verify the specific numerical details of the updated fiscal year 2025 financial guidance in the press release (Exhibit 99.2).
- Review the Unaudited Pro Forma Condensed Consolidated Financial Information (Exhibit 99.1) to assess the post-transaction balance sheet and liquidity position.
- Examine the Restrictive Covenant Agreement (Exhibit 10.1) to understand the precise scope of non-compete limitations on future business expansion.
- Confirm the terms of the Commercial Agreement (Exhibit 10.2) regarding the nature and pricing of medical transport services to be provided by Joby Buyer.
- Monitor the satisfaction of employee retention and financial performance targets required to unlock the potential $35.0 million in additional consideration.